TY - JOUR
T1 - Restaging MRI of Rectal Adenocarcinoma after Neoadjuvant Chemoradiotherapy
T2 - Imaging Findings and Potential Pitfalls
AU - Awiwi, Muhammad O.
AU - Kaur, Harmeet
AU - Ernst, Randy
AU - Rauch, Gaiane M.
AU - Morani, Ajaykumar C.
AU - Stanietzky, Nir
AU - Palmquist, Sarah M.
AU - Salem, Usama I.
N1 - Publisher Copyright:
© RSNA, 2023.
PY - 2023/4
Y1 - 2023/4
N2 - Rectal adenocarcinoma constitutes about one-third of all colorectal adenocarcinoma cases. Rectal MRI has become mandatory for evaluation of patients newly diagnosed with rectal cancer because it can help accurately stage the disease, impact the choice to give neoadjuvant therapy or proceed with up-front surgery, and even direct surgical dissection planes. Better understanding of neoad-juvant chemoradiotherapy effects on rectal tumors and recognition that up to 30% of patients can have a pathologic complete response have opened the door for the nonsurgical “watch-and-wait” management approach for rectal adenocarcinoma. Candidates for this organ-preserving approach should have no evidence of malignancy on all three components of response assessment after neoadjuvant therapy (ie, digital rectal examination, endoscopy, and rectal MRI). Hence, rectal MRI again has a major role in direct-ing patient management and possibly sparing patients from unnecessary surgical morbidity. In this article, the authors discuss the indications for neoadjuvant therapy in management of patients with rectal adenocarcinoma, describe expected imaging appear-ances of rectal adenocarcinoma after completion of neoadjuvant therapy, and outline the MRI tumor regression grading system. Since pelvic sidewall lymph node dissection is associated with a high risk of permanent genitourinary dysfunction, it is performed for only selected patients who have radiologic evidence of sidewall lymph node involvement. Therefore, the authors review the relevant lymphatic compartments of the pelvis and describe lymph node criteria for determining locoregional nodal spread. Finally, the authors discuss limitations of rectal MRI, describe several potential interpretation pitfalls after neoadjuvant therapy, and em-phasize how these pitfalls may be avoided.
AB - Rectal adenocarcinoma constitutes about one-third of all colorectal adenocarcinoma cases. Rectal MRI has become mandatory for evaluation of patients newly diagnosed with rectal cancer because it can help accurately stage the disease, impact the choice to give neoadjuvant therapy or proceed with up-front surgery, and even direct surgical dissection planes. Better understanding of neoad-juvant chemoradiotherapy effects on rectal tumors and recognition that up to 30% of patients can have a pathologic complete response have opened the door for the nonsurgical “watch-and-wait” management approach for rectal adenocarcinoma. Candidates for this organ-preserving approach should have no evidence of malignancy on all three components of response assessment after neoadjuvant therapy (ie, digital rectal examination, endoscopy, and rectal MRI). Hence, rectal MRI again has a major role in direct-ing patient management and possibly sparing patients from unnecessary surgical morbidity. In this article, the authors discuss the indications for neoadjuvant therapy in management of patients with rectal adenocarcinoma, describe expected imaging appear-ances of rectal adenocarcinoma after completion of neoadjuvant therapy, and outline the MRI tumor regression grading system. Since pelvic sidewall lymph node dissection is associated with a high risk of permanent genitourinary dysfunction, it is performed for only selected patients who have radiologic evidence of sidewall lymph node involvement. Therefore, the authors review the relevant lymphatic compartments of the pelvis and describe lymph node criteria for determining locoregional nodal spread. Finally, the authors discuss limitations of rectal MRI, describe several potential interpretation pitfalls after neoadjuvant therapy, and em-phasize how these pitfalls may be avoided.
UR - http://www.scopus.com/inward/record.url?scp=85150315009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150315009&partnerID=8YFLogxK
U2 - 10.1148/rg.220135
DO - 10.1148/rg.220135
M3 - Article
C2 - 36927125
AN - SCOPUS:85150315009
SN - 0271-5333
VL - 43
JO - Radiographics
JF - Radiographics
IS - 4
M1 - e220135
ER -